Raloxifene (Evista)
Prescription SERM for bone loss after menopause, also used by men for breast enlargement; its main risk is venous blood clots.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

DETAILED OVERVIEW
What is Raloxifene (Evista)?
Raloxifene is a prescription medicine sold as Evista. It is a selective estrogen receptor modulator (SERM): it blocks estrogen in the breast and womb but partly imitates it in bone. In the United States it was approved in 1997 for bone loss after menopause, and later also to prevent breast cancer in high-risk women. Men using anabolic steroids also use it to reverse breast enlargement (gynecomastia); only a few small studies in adolescents exist for this.
Its most serious risk is venous blood clots (deep vein thrombosis, pulmonary embolism). The US prescribing information carries its strongest, boxed warning about this: the risk is about three times higher than with placebo. In people with existing coronary artery disease or high cardiovascular risk, deaths from stroke also increased. Hot flashes are very common. It must not be used in pregnancy, because it can harm the baby. It is on the anti-doping list and banned for male athletes.
Mechanism
Benzothiophene SERM, ER-α antagonist in breast+uterus, agonist in bone
Half-life
~27 h (once-daily dose)
Onset
Gyno-tissue regression 6-12 weeks
Legal status
FDA + EMA Rx (postmenopausal osteo + breast-cancer prevention), WADA S4 (banned)
No anecdote collected yet.
Data console
Lab data
Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC . The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.. JAMA.
Vogel VG, Costantino JP, Wickerham DL, et al. . Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727-41..
Lawrence SE, Faught KA, Vethamuthu J, Lawson ML . Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia.. J Pediatr.
Malozowski S, Stadel BV . Treatment of adolescents with gynecomastia.. J Pediatr.
Safety
Side effects, stop signs, contraindications
Side effects · 6
- Venous thromboembolism (deep vein thrombosis, pulmonary embolism) – FDA Evista black-box warning, roughly 3-fold increased relative risk vs placebo, highest during the first 4 months.
- Hot flashes – common (around 25-30%), especially in the first months of treatment, a consequence of the SERM estrogen-antagonist effect.
- Leg cramps and muscle spasms – well-documented, common adverse effect in the Evista trials.
- Peripheral edema (fluid retention, leg swelling) – a common complaint.
- Flu-like syndrome, joint pain (arthralgia) and sweating – among the milder, frequently reported side effects.
- Increased risk of fatal stroke documented in women with proven coronary heart disease or at high cardiovascular risk (RUTH trial) – overall stroke incidence was not raised, but fatal outcomes were.
Contraindications · 7
- Active or past venous thromboembolic event (deep vein thrombosis, pulmonary embolism, retinal vein thrombosis) – absolute contraindication per FDA Evista label.
- Pregnancy and women who may become pregnant, plus breastfeeding – Pregnancy Category X, teratogenic, contraindicated in women of childbearing potential.
- Prolonged immobilization (post-surgical recovery, long travel, bed rest) – due to VTE risk; should be stopped at least 72 hours before immobilization and not resumed until full mobility returns.
- Established coronary heart disease, prior stroke or high cardiovascular risk – fatal stroke risk was increased in the RUTH trial.
- Severe hepatic impairment (liver insufficiency) – insufficient safety data, caution or avoidance advised.
- Severe renal impairment – limited data, cautious use required.
- Unexplained uterine bleeding or endometrial abnormality – must be investigated before starting raloxifene.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial
Vogel VG, Costantino JP, Wickerham DL, et al.
Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia.
Lawrence SE, Faught KA, Vethamuthu J, Lawson ML
Treatment of adolescents with gynecomastia.
Malozowski S, Stadel BV
Telegram
Have a question about Raloxifene (Evista)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.


